1 ampoule with 1 mL injection solution contains 1000 ug hydroxocobalamin acetate
Individuals most likely to benefit include: Those with pernicious anemia People with gastrointestinal disorders (e.g., Crohns disease, celiac disease, chronic gastritis) Patients following bariatric (weight loss) surgery Older adults with absorption difficulties Strict vegetarians or vegans at risk for deficiency People taking medications that can decrease vitamin B12 levels Laboratory testing usually confirms B12 deficiency before starting injections
Phase 2b clinical trials were completed in Australia testing the drug in 300 obese individuals
SLU-PP-332, 5mg SLU-PP-332 is a metabolic research compound studied in exercise-mimetic pathways, energy expenditure models, and ERR receptor signaling
American Pregnancy Association
Address 1307 N Cutting Avenue Jennings, LA 70546 Hours Mon & Fri: Closed Tues - Thurs: 8am 5pm *Closed for lunch 1-2pm